At the time of writing, Stoke Therapeutics Inc [STOK] stock is trading at $10.05, up 2.24%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The STOK shares have gain 12.54% over the last week, with a monthly amount glided 16.72%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Stoke Therapeutics Inc [NASDAQ: STOK] stock has seen the most recent analyst activity on December 20, 2024, when Chardan Capital Markets initiated its Buy rating and assigned the stock a price target of $24. On March 26, 2024, upgrade upgraded it’s rating to Outperform. TD Cowen downgraded its rating to a Market Perform. BofA Securities upgraded its rating to Neutral for this stock on May 01, 2023, and upped its price target to $12.
For the past year, the stock price of Stoke Therapeutics Inc fluctuated between $5.35 and $17.58. Currently, Wall Street analysts expect the stock to reach $30.6 within the next 12 months. Stoke Therapeutics Inc [NASDAQ: STOK] shares were valued at $10.05 at the most recent close of the market. An investor can expect a potential return of 204.48% based on the average STOK price forecast.
Analyzing the STOK fundamentals
According to Stoke Therapeutics Inc [NASDAQ:STOK], the company’s sales were 190.91M for trailing twelve months, which represents an 3661.12% jump. Gross Profit Margin for this corporation currently stands at 0.15% with Operating Profit Margin at 0.2%, Pretax Profit Margin comes in at 0.27%, and Net Profit Margin reading is 0.26%. To continue investigating profitability, this company’s Return on Assets is posted at 0.12, Equity is 0.19 and Total Capital is 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Stoke Therapeutics Inc [NASDAQ:STOK] has a current ratio of 8.41. Further, the Quick Ratio stands at 8.41, while the Cash Ratio is 6.15. Considering the valuation of this stock, the price to sales ratio is 2.87, the price to book ratio is 1.57 and price to earnings (TTM) ratio is 12.77.
Transactions by insiders
Recent insider trading involved Ticho Barry, CHIEF MEDICAL OFFICER, that happened on May 02 ’25 when 22790.0 shares were sold. CHIEF MEDICAL OFFICER, Ticho Barry completed a deal on May 01 ’25 to sell 3841.0 shares. Meanwhile, Officer BARUCH S. TICHO bought 34847.0 shares on May 01 ’25.
